Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Cardio Diagnostics Holdings Inc
Research & Development
Cardio Diagnostics Holdings Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
Research & Development
-$29.1k
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Research & Development
-$600m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
Schlumberger NV
NYSE:SLB
|
Research & Development
-$709m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
|
Halliburton Co
NYSE:HAL
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Research & Development
-$196m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Research & Development
-$783.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Cardio Diagnostics Holdings Inc
Glance View
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
See Also
What is Cardio Diagnostics Holdings Inc's Research & Development?
Research & Development
-29.1k
USD
Based on the financial report for Dec 31, 2024, Cardio Diagnostics Holdings Inc's Research & Development amounts to -29.1k USD.
What is Cardio Diagnostics Holdings Inc's Research & Development growth rate?
Research & Development CAGR 3Y
1%
Over the last year, the Research & Development growth was 80%. The average annual Research & Development growth rates for Cardio Diagnostics Holdings Inc have been 1% over the past three years .
